Adding EV and pembrolizumab to surgical treatment can improve outcomes in MIBC patients who are ineligible for cisplatin, data suggest.

Adding nimotuzumab to post-surgery adjuvant cisplatin-based chemoradiotherapy does not improve survival outcomes in patients with HNSCC.

Administering durvalumab before and after CRT did not provide a benefit over CRT alone in a phase 3 trial of patients with intermediate- and high-risk oropharyngeal cancer.

Data from a phase 1/2 study support the use of sevabertinib in patients with HER2-mutated NSCLC, an investigator says.

Tiragolumab plus atezolizumab does not improve survival compared to durvalumab in locally advanced, unresectable, stage 3 NSCLC.